RESUMO
The number of annual THA's, TKA's, and TSA's is set to increase significantly by the year 2030, making it imperative to understand the risks for negative outcomes in these procedures. While research has studied the patient risk factors for perioperative and postoperative complications, there has been relatively little research for intraoperative complications. After a thorough literature review, the most supported finding was that patients with a BMI >30 had significantly more intraoperative blood loss than those with a BMI <30. All other relationships between patient risk factors and intraoperative complications of interest were inadequately studied.
Assuntos
Artroplastia de Substituição/efeitos adversos , Interações Medicamentosas/genética , Dor Pós-Operatória , Testes Farmacogenômicos , Variantes Farmacogenômicos/genética , Subfamília B de Transportador de Cassetes de Ligação de ATP/genética , Analgésicos Opioides/uso terapêutico , Humanos , Dor Pós-Operatória/tratamento farmacológico , Dor Pós-Operatória/genéticaAssuntos
Artroplastia de Substituição , Índice de Massa Corporal , Desnutrição , Estado Nutricional/fisiologia , Cuidados Pré-Operatórios/métodos , Humanos , Desnutrição/complicações , Desnutrição/diagnóstico , Avaliação Nutricional , Complicações Pós-Operatórias/etiologia , Complicações Pós-Operatórias/prevenção & controle , Resultado do Tratamento , CicatrizaçãoAssuntos
Analgésicos Opioides/farmacologia , Artroplastia de Quadril , Artroplastia do Joelho , Família 3 do Citocromo P450/farmacologia , Dor Pós-Operatória/prevenção & controle , Farmacogenética , Analgésicos Opioides/uso terapêutico , Artroplastia de Quadril/efeitos adversos , Artroplastia do Joelho/efeitos adversos , Família 3 do Citocromo P450/uso terapêutico , Humanos , Manejo da Dor , Dor Pós-Operatória/tratamento farmacológicoRESUMO
Eight patients with primary (n = 6) and metastatic (n = 2) disease of the liver underwent yttrium-90 radioembolization with glass microspheres using a combination of segmental and ipsilateral lobar approach to treat multifocal tumors containing a single dominant tumor. The superselective dose was administered to the dominant tumor, whereas lobar infusion was used for smaller tumors. Assuming uniform distribution, median dose to the segment with dominant tumor was 412.3 Gy and to the remaining lobe was 117.5 Gy. No instances of radiation-induced liver disease occurred. Combined segmental and ipsilateral lobar radioembolization is a well-tolerated procedure to treat unilateral multifocal hepatic tumors including a single dominant tumor.
